BioAmber price target lowered to $1.75 from $12 at H.C. Wainwright H.C. Wainwright analyst Amit Dayal lowered his price target for BioAmber to $1.75 to reflect developments around the ramping to full utilization of existing capacity at Sarnia and the build out of new capacity. The analyst believes improved demand supported the company's turnaround effort. He keeps a Buy rating on the shares following the Q4 results
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.